Regeneron Pharmaceuticals Inc (REGN)

455.17
0.53 0.12
NASDAQ : Health Care
Prev Close 455.70
Open 456.70
Day Low/High 453.35 / 459.25
52 Wk Low/High 329.09 / 605.93
Volume 475.52K
Avg Volume 924.00K
Exchange NASDAQ
Shares Outstanding 106.29M
Market Cap 48.44B
EPS 6.20
P/E Ratio 55.10
Div & Yield N.A. (N.A)

Latest News

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.

Biotech Movers: Horizon, OncoMed, Inovio

Biotech Movers: Horizon, OncoMed, Inovio

Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.

Oil Slide Puts Market Into Rotation: Cramer's 'Mad Money' Recap (Thursday 5/4/17)

Oil Slide Puts Market Into Rotation: Cramer's 'Mad Money' Recap (Thursday 5/4/17)

Gyrations hit market, as traders drop oil, buy safety.

Regeneron Shares Rise After Reporting Better-Than-Expected Sales

Regeneron Shares Rise After Reporting Better-Than-Expected Sales

The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.

Regeneron Shows Green Shoots

Regeneron Shows Green Shoots

Clues in the chart point to higher prices to come.

Chart of the Day: Regeneron

Clues in the chart point to higher prices to come.

Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round

Wingstop, Sanofi, Micron Technology: 'Mad Money' Lightning Round

Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.

Sanofi And Regeneron Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

- Monthly dosing schedule now approved in both United States and European Union -

Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent® (alirocumab) Injection

Monthly dosing schedule now approved in both United States and European Union

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Cramer: Retail Rally Shows the Perils of Being Too Negative

Cramer: Retail Rally Shows the Perils of Being Too Negative

There's a forest fire in the sector.

Regeneron Is Ready to Rally

Regeneron Is Ready to Rally

An upside breakout appears on the horizon.

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron and Sanofi will launch Dupixent with a gross sticker price of $37,000 per year, before insurance discounts and rebates.

European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details

European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details

European stocks drifted lower Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.

European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade

European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade

European stocks are expected to open mixed Monday following a holiday-thinned trading session in Asia as investors prepare for key inflation and private sector activity data later in the week.

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Dow, S&P 500 Decline as Health Care Losses Counter Gains

Wall Street ends a jampacked week little changed as a selloff in health care stocks counters broad gains elsewhere.

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Broad Gains Overshadow Health Care Losses to Boost Wall Street

Stocks rise on Friday even as a selloff in health care extends into its second day.

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks Creep Lower as Health Care Selloff Extends Into Day 2

Stocks creep lower on Friday as a selloff in health care extends into its second day.

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate

Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?

Teen Scientist Researches New Approach To Neurological Damage; Wins Regeneron Science Talent Search 2017

Indrani Das of New Jersey Wins $250,000 Top Award in Nation's Oldest and Most Prestigious High School Science and Mathematics Competition

Teen Scientist Researches New Approach To Neurological Damage; Wins Regeneron Science Talent Search 2017

Indrani Das of New Jersey Wins $250,000 Top Award in Nation's Oldest and Most Prestigious High School Science and Mathematics Competition

Regeneron Could Generate More Upside

Regeneron Could Generate More Upside

Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.

Regeneron Is Ready to Reanimate: Watch for a Breakout

Regeneron Is Ready to Reanimate: Watch for a Breakout

This stock is testing resistance and could push back up to last year's highs.

Regeneron Could Run Higher: Must-See Chart

Regeneron Could Run Higher: Must-See Chart

Shares of biotech giant Regeneron broke out on Thursday and are setting up well for a fresh rally leg.

Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)

Don't Give the Fed Credit for This Bull: Cramer's 'Mad Money' Recap (Thursday 3/9/17)

Big market gains were the result of great companies, CEOs and the people behind them -- not just the Fed, says Jim Cramer.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.